KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Net Income towards Common Stockholders rose 5.58% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.90% up from last year.
  • Per Nektar Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$35.0 million for Q3 2025, which was up 10.76% from -$39.2 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Net Income towards Common Stockholders registered a high of $7.2 million during Q4 2024, and its lowest value of -$159.1 million during Q2 2022.
  • For the 3-year period, Nektar Therapeutics' Net Income towards Common Stockholders averaged around -$46.9 million, with its median value being -$42.1 million (2023).
  • As far as peak fluctuations go, Nektar Therapeutics' Net Income towards Common Stockholders slumped by 56.90% in 2021, and later soared by 117.19% in 2024.
  • Nektar Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$146.9 million in 2021, then skyrocketed by 54.66% to -$66.6 million in 2022, then soared by 36.82% to -$42.1 million in 2023, then surged by 117.19% to $7.2 million in 2024, then rose by 5.58% to -$35.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$35.0 million for Q3 2025, versus -$39.2 million for Q2 2025 and -$46.4 million for Q1 2025.